NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19th Annual BIO CEO & Investor Conference in New York at 5:30 pm eastern time on Monday, February 13, 2017.
A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: [email protected] 650-635-7000 Media: JPA Health Communications Nic DiBella [email protected] 617-945-5183
